Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review

Table 1 Baseline and main characteristics of the enrolled records

Study	Condition	Drug	Dose	Year	Number of participants(N)	LVEF (%), Mean	Follow-up time,Mean	Age(y), Mean	Male (%)	Diabetes (%)	eGFR < 60 ml/min/1.73 m (%)	ACEi/ARB/ARNi (N)	Beta-blocker (N)	MRA (N)
DAPA-HF	HFrEF	Dapagliflozin	10 mg	2019	4744	31.10%	18.2 months	66.3	76.60%	42.00%	41%	4459	4554	3368
DETERMINE-reduced	HFrEF	Dapagliflozin	10 mg	2021	313	NA	16 weeks	67.8	74.40%	NA	NA	NA	NA	NA
DETERMINE-preserved	HFpEF	Dapagliflozin	10 mg	2020	504	NA	16 weeks	71.8	63.50%	NA	NA	NA	NA	NA
DEFINE-HF	HFrEF	Dapagliflozin	10 mg	2019	263	26.40%	13 weeks	61.3	73.40%	63.10%	NA	241	256	160
PRESERVED-HF	HFpEF	Dapagliflozin	10 mg	2022	324	NA	12 weeks	70	43.20%	55.60%	NA	NA	NA	NA
EMPERIAL-Reduced	HFrEF	Empagliflozin	10 mg	2020	312	NA	12 weeks	69	74.40%	NA	NA	287	295	182
EMPERIAL-Preserved	HFpEF	Empagliflozin	10 mg	2020	315	NA	12 weeks	73.5	56.80%	NA	NA	246	281	105
EMPEROR-Reduced	HFrEF	Empagliflozin	10 mg	2020	3730	27.40%	16 months	66.8	76.10%	49.70%	48%	3327	3533	2661
EMPEROR-Preserved	HFpEF	Empagliflozin	10 mg	2020	5988	NA	26.2 months	71.8	55.30%	48.90%	24.88%	4839	5164	2240
SUGAR-DM-HF	HFrEF	Empagliflozin	10 mg	2022	205	32.50%	36 weeks	68.7	73.30%	78.10%	50.20%	NA	NA	NA

ACEi = angiotension converting enzyme inhibitors; ARB = angiotonin receptor blocker; ARNi = angiotensin receptor enkephalase inhibitors; eGFR = estimated glomerular filtration rate; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NA = not applicable; T2DM = type 2 diabetes;

ISSN: 1475-2840